Verona Pharma plc - VRNA STOCK NEWS

Verona Pharma plc (Nasdaq: VRNA), a clinical-stage biopharmaceutical firm specializing in respiratory diseases, has announced that CEO David Zaccardelli will provide a company overview at the H.C. Wainwright Global Life Sciences Conference. The presentation will be accessible on-demand starting 7:00 AM ET on March 9, 2021. It will be available for 90 days on the company’s Investors page. Verona Pharma is focused on developing ensifentrine, aimed at treating chronic obstructive pulmonary disease (COPD) with unique bronchodilator and anti-inflammatory properties.

Verona Pharma (VRNA) announced positive Phase 2 results for ensifentrine in COPD and ongoing enrollment in the Phase 3 ENHANCE program. The company secured a $30 million debt finance facility, enhancing financial flexibility. For Q4 2020, the net loss was $24.8 million, an increase from $9.5 million in Q4 2019. Cash and equivalents stood at $188 million at the end of 2020, bolstered by a $200 million private placement. The company expects to report top-line data from COVID-19 and ENHANCE studies in 2021 and 2022, respectively.

Verona Pharma (Nasdaq: VRNA) will report its fourth quarter and full year financial results for 2020 on February 25, 2021. A conference call for investors will take place at 9:00 a.m. EST / 2:00 p.m. GMT to discuss these results and provide a corporate update. The company is known for developing therapies for respiratory diseases, notably ensifentrine, which is in Phase 3 trials for COPD treatment. The funds from a $200 million private placement in July 2020 are expected to support operations into 2023.

Verona Pharma announces the presentation of new analyses from a Phase 2b clinical trial of ensifentrine for chronic obstructive pulmonary disease (COPD) at the CHEST Annual Meeting 2020. The data indicate that adding nebulized ensifentrine to tiotropium provides significant improvements in quality of life and inspiratory capacity over four weeks. Furthermore, additional analyses highlight a rapid bronchodilator response with a pressurized metered-dose inhaler (pMDI) formulation, sustained for 12 hours. This data suggests ensifentrine’s dual mechanism of action may effectively manage COPD symptoms.

Verona Pharma announced the initiation of its Phase 3 ENHANCE trials for nebulized ensifentrine, targeting patients with moderate to severe COPD. This pivotal study aims to demonstrate the efficacy and safety of ensifentrine, potentially paving the way for a New Drug Application in the U.S. if successful. Previous studies show ensifentrine's ability to improve lung function, symptoms, and quality of life in COPD patients. The ENHANCE trials will involve approximately 1,600 patients across the U.S. and Europe, assessing ensifentrine's effects over 24-48 weeks.

Verona Pharma announced the publication of a detailed analysis from a Phase 2b clinical trial of nebulized ensifentrine for COPD treatment in the International Journal of Chronic Obstructive Pulmonary Disease. The study, involving 405 patients, showed significant improvements in COPD symptoms within 4 weeks, notably in breathlessness, cough, and overall quality of life. Ensifentrine, a dual PDE3/PDE4 inhibitor, combines bronchodilation and anti-inflammatory effects. Positive outcomes from previous trials enhance its potential as a novel COPD therapy.

Verona Pharma (Nasdaq: VRNA) has initiated a pilot study to assess the efficacy and safety of ensifentrine delivered via a pressurized metered-dose inhaler (pMDI) in COVID-19 patients in the U.S. This randomized study will involve approximately 45 hospitalized patients, evaluating the compound's potential to improve recovery, clinical status, and reduce oxygen use. Ensifentrine has shown promise in previous trials for respiratory diseases, demonstrating improvements in lung function and safety. Successful outcomes could position ensifentrine as a novel COVID-19 treatment.

Verona Pharma (Nasdaq: VRNA) has announced that David Zaccardelli, CEO, will present a company overview at the H.C. Wainwright 22nd Annual Global Virtual Investment Conference on September 14, 2020, at 5:00 PM ET. A live webcast will be available on the company’s website, with an audio replay for 30 days. Verona Pharma focuses on respiratory diseases, with its lead product candidate, ensifentrine, aiming to combine bronchodilator and anti-inflammatory effects, with a Phase 3 program expected to start later in 2020.

Verona Pharma announced the grant of 6,794,521 Restricted American Depositary Share Units (RADSUs) to its directors and employees, representing 54,356,168 ordinary shares, or 13.11% of its total voting rights. The grants, made under the 2017 Incentive Award Plan, include notable allocations to CEO David Zaccardelli (1,785,203 RADSUs) and CFO Mark Hahn (1,916,861 RADSUs). Vesting schedules vary, with some shares set to vest incrementally over the next few years. The grants follow shareholder approval at the annual meeting on April 16, 2020, for additional share issuance authority.